FDA Pushes for Prescription Drugs to Become Over-the-Counter
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 18 2026
0mins
Should l Buy GILD?
Source: CNBC
- Policy Advocacy: FDA Commissioner Marty Makary stated in Washington that the agency plans to push for more prescription drugs to become over-the-counter (OTC) this year, aiming to improve drug accessibility and reduce healthcare costs, which could allow patients to obtain basic safe medications without a doctor's visit.
- Regulatory Streamlining: Legislation passed by Congress in November simplifies the regulatory process for transitioning prescription drugs to OTC status, including full, conditional, and partial switch pathways, which is expected to accelerate drug availability and enhance patient convenience in medication access.
- Increased Transparency: Makary emphasized that OTC sales would bypass insurers and pharmacy benefit managers, potentially lowering drug prices and increasing transparency, with cash prices for OTC medications possibly being lower than patients' copays for prescription drugs, thereby alleviating financial burdens on patients.
- Industry Pushback: The pharmaceutical industry has raised concerns about this policy, arguing that OTC drugs may not be covered by insurance, leading to higher costs for patients, and that the FDA lacks authority over drug pricing, necessitating thorough consultations with manufacturers before any transitions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GILD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GILD
Wall Street analysts forecast GILD stock price to fall
19 Analyst Rating
16 Buy
3 Hold
0 Sell
Strong Buy
Current: 148.950
Low
105.00
Averages
137.88
High
154.00
Current: 148.950
Low
105.00
Averages
137.88
High
154.00
About GILD
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. It is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. It also develops the HB-400 program and the HB-500 program. It develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. It has a cancer program, namely TREX1. It operates in more than 35 countries worldwide.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Gilead Foundation Invests $12 Million to Strengthen HIV Prevention Efforts
- Investment Scale: Gilead Foundation announced a $12 million investment in 33 community organizations nationwide to support its Community Health Worker Comprehensive HIV Prevention Initiative, aiming to enhance the accessibility and effectiveness of HIV prevention services over the next two years.
- Community Impact: The initiative prioritizes communities most affected by HIV, including Black and Latino men, transgender women, and youth, aiming to reduce health disparities by providing tailored education and prevention services.
- Organizational Infrastructure: Funded organizations will strengthen training systems for community health workers and build sustainable HIV prevention networks, thereby enhancing community trust and engagement in health services.
- Long-term Vision: Gilead Sciences plans to invest $32 billion by 2025 to further strengthen its U.S. operations, driving public health preparedness and scientific innovation to ensure patients worldwide benefit from its medical breakthroughs.
See More
Significant Milestones in Biotech Sector This Week
- FDA Drug Approvals: Armata Pharmaceuticals' AP-SA02 received FDA's QIDP designation, granting five years of market exclusivity and paving the way for a Phase 3 trial in 2026, which is expected to significantly enhance the company's competitive edge in the antibiotic market.
- Weight Loss Innovation: Allurion Technologies' gastric balloon system gained FDA approval, offering a non-surgical weight loss option for patients with a BMI of 30-40, which is anticipated to expand the company's market share in the obesity sector.
- Acquisition Deal: Gilead Sciences is acquiring Arcellx for $115 per share, totaling $7.8 billion, a move that will strengthen Gilead's position in cell therapy and enhance its collaboration with Kite Pharma.
- Clinical Trial Developments: Novo Nordisk's CagriSema missed key goals in its trial against Zepbound, although it demonstrated a favorable safety profile, which may influence future market strategies.
See More
Novartis and Genentech Sue Over Drug Importation
- Drug Import Lawsuit: Novartis and Genentech have filed a lawsuit against a U.S. company and a Canadian pharmacy for the illegal importation of the allergy medication Xolair, which poses potential risks to patient safety, seeking a court order to halt this practice.
- FDA Regulatory Violations: The lawsuit claims that this importation violates U.S. Food and Drug Administration regulations, as biological medicines like Xolair are highly sensitive to storage and handling conditions, which could lead to contamination and reduced efficacy.
- Rise of Alternative Funding Programs: A CNBC investigation reveals a growing number of alternative funding programs in the U.S., despite federal officials warning that such imports are illegal and could jeopardize patient health.
- Patient Safety Risks: The lawsuit underscores that importing unapproved medications can result in serious patient injuries or even death, with Novartis and Genentech aiming to protect patients from these potential health threats.
See More
Novartis and Genentech Sue Over Illegal Drug Import Scheme
- Illegal Drug Importation: Novartis and Genentech have filed a lawsuit against SHARx and a Canadian pharmacy for allegedly violating FDA regulations by illegally importing the allergy medication Xolair from Canada to the U.S., posing potential health risks to patients.
- Legal Action Context: The lawsuit, filed on February 2 in the U.S. District Court in Michigan, seeks to halt the importation of the drug, emphasizing the sensitivity of biological medicines to storage and handling conditions, which could lead to contamination and degradation.
- Patient Safety Risks: The complaint highlights that importing unapproved drugs can result in serious patient injuries or even death, stressing the strict temperature control requirements during drug transport, thereby underscoring the dangers of such practices.
- Market Regulation Challenges: This case reflects the growing legal gray area surrounding alternative funding programs (AFPs) in drug access, with federal authorities warning about the illegality of such imports, which could threaten patient health.
See More
Analysis of DFAC Stock's 52-Week High and Low Points
- Price Fluctuation Analysis: DFAC's 52-week low is $28.39 and high is $41.64, with the latest trade at $41.00, indicating the stock is nearing its high point, which may attract investor interest.
- Technical Analysis Tool: Comparing the latest stock price to the 200-day moving average can provide valuable insights for investors, helping to assess market trends.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting ETF liquidity.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding for ETFs helps identify those experiencing significant inflows or outflows, allowing assessment of their potential impact on underlying assets.
See More
Barron’s Top Fund Families for 2025
Opportunity for Fund Managers: Last year provided a significant opportunity for skilled fund managers to demonstrate their capabilities in navigating market challenges.
Market Conditions: The financial landscape presented unique conditions that allowed for strategic investment decisions and potential gains.
Performance Evaluation: The year served as a benchmark for assessing the effectiveness and decision-making skills of fund managers.
Investor Expectations: Investors were keenly observing how fund managers adapted to the evolving market, influencing future investment strategies.
See More
Gilead Foundation Invests $12 Million to Strengthen HIV Prevention Efforts
- Investment Scale: Gilead Foundation announced a $12 million investment in 33 community organizations nationwide to support its Community Health Worker Comprehensive HIV Prevention Initiative, aiming to enhance the accessibility and effectiveness of HIV prevention services over the next two years.
- Community Impact: The initiative prioritizes communities most affected by HIV, including Black and Latino men, transgender women, and youth, aiming to reduce health disparities by providing tailored education and prevention services.
- Organizational Infrastructure: Funded organizations will strengthen training systems for community health workers and build sustainable HIV prevention networks, thereby enhancing community trust and engagement in health services.
- Long-term Vision: Gilead Sciences plans to invest $32 billion by 2025 to further strengthen its U.S. operations, driving public health preparedness and scientific innovation to ensure patients worldwide benefit from its medical breakthroughs.
See More
Significant Milestones in Biotech Sector This Week
- FDA Drug Approvals: Armata Pharmaceuticals' AP-SA02 received FDA's QIDP designation, granting five years of market exclusivity and paving the way for a Phase 3 trial in 2026, which is expected to significantly enhance the company's competitive edge in the antibiotic market.
- Weight Loss Innovation: Allurion Technologies' gastric balloon system gained FDA approval, offering a non-surgical weight loss option for patients with a BMI of 30-40, which is anticipated to expand the company's market share in the obesity sector.
- Acquisition Deal: Gilead Sciences is acquiring Arcellx for $115 per share, totaling $7.8 billion, a move that will strengthen Gilead's position in cell therapy and enhance its collaboration with Kite Pharma.
- Clinical Trial Developments: Novo Nordisk's CagriSema missed key goals in its trial against Zepbound, although it demonstrated a favorable safety profile, which may influence future market strategies.
See More
Novartis and Genentech Sue Over Drug Importation
- Drug Import Lawsuit: Novartis and Genentech have filed a lawsuit against a U.S. company and a Canadian pharmacy for the illegal importation of the allergy medication Xolair, which poses potential risks to patient safety, seeking a court order to halt this practice.
- FDA Regulatory Violations: The lawsuit claims that this importation violates U.S. Food and Drug Administration regulations, as biological medicines like Xolair are highly sensitive to storage and handling conditions, which could lead to contamination and reduced efficacy.
- Rise of Alternative Funding Programs: A CNBC investigation reveals a growing number of alternative funding programs in the U.S., despite federal officials warning that such imports are illegal and could jeopardize patient health.
- Patient Safety Risks: The lawsuit underscores that importing unapproved medications can result in serious patient injuries or even death, with Novartis and Genentech aiming to protect patients from these potential health threats.
See More
Novartis and Genentech Sue Over Illegal Drug Import Scheme
- Illegal Drug Importation: Novartis and Genentech have filed a lawsuit against SHARx and a Canadian pharmacy for allegedly violating FDA regulations by illegally importing the allergy medication Xolair from Canada to the U.S., posing potential health risks to patients.
- Legal Action Context: The lawsuit, filed on February 2 in the U.S. District Court in Michigan, seeks to halt the importation of the drug, emphasizing the sensitivity of biological medicines to storage and handling conditions, which could lead to contamination and degradation.
- Patient Safety Risks: The complaint highlights that importing unapproved drugs can result in serious patient injuries or even death, stressing the strict temperature control requirements during drug transport, thereby underscoring the dangers of such practices.
- Market Regulation Challenges: This case reflects the growing legal gray area surrounding alternative funding programs (AFPs) in drug access, with federal authorities warning about the illegality of such imports, which could threaten patient health.
See More
Analysis of DFAC Stock's 52-Week High and Low Points
- Price Fluctuation Analysis: DFAC's 52-week low is $28.39 and high is $41.64, with the latest trade at $41.00, indicating the stock is nearing its high point, which may attract investor interest.
- Technical Analysis Tool: Comparing the latest stock price to the 200-day moving average can provide valuable insights for investors, helping to assess market trends.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting ETF liquidity.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding for ETFs helps identify those experiencing significant inflows or outflows, allowing assessment of their potential impact on underlying assets.
See More
Barron’s Top Fund Families for 2025
Opportunity for Fund Managers: Last year provided a significant opportunity for skilled fund managers to demonstrate their capabilities in navigating market challenges.
Market Conditions: The financial landscape presented unique conditions that allowed for strategic investment decisions and potential gains.
Performance Evaluation: The year served as a benchmark for assessing the effectiveness and decision-making skills of fund managers.
Investor Expectations: Investors were keenly observing how fund managers adapted to the evolving market, influencing future investment strategies.
See More
